Navigation Links
Genelux, a Leader in the Emerging Oncolytic Virotherapy Field, Receives Significant Industry Honor from Elsevier Business Intelligence, Identifying GL-ONC1 as One of 2013's 'Top Oncology Projects to Watch'
Date:11/18/2013

SAN DIEGO, Nov. 18, 2013 /PRNewswire/ -- Genelux Corporation, a leader in the emerging field of oncolytic virotherapy, announced today that the Company's lead product candidate, GL-ONC1, has been selected by Elsevier Business Intelligence as one of its 2013 "Top 10 Oncology Projects to Watch." Genelux will present its vaccinia-based proprietary platform technology at the Elsevier Business Intelligence Therapeutic Area Partnerships (TAP) Conference, one of the pharmaceutical industry's premier partnering events, November 18-20 in Boston.

"Selection as a 'Top 10 Oncology Project to Watch' by Elsevier represents a significant industry honor," said Dr. Aladar Szalay, Founder, President and CEO of Genelux Corporation. "We are very proud of the progress we have made in developing GL-ONC1 for the diagnosis and treatment of a number of difficult-to-treat cancers, as well as our exciting pipeline of future product candidates. Our team looks forward to discussing the science behind the Genelux oncolytic vaccinia-based platform, the GL-ONC1 program and the Company's future plans at the TAP conference."

Elsevier considered various criteria when selecting the Top 10 Programs, including the history of the molecule or drug, the diversity of indications – initial and future, and multi-level partnering prospects. "Select companies have been screened using a strict set of judging criteria for the Top 10 awards and represent what our committees consider among the most attractive opportunities the industry has to offer," said David Cassak, Vice President, Content, Elsevier Business Intelligence. "Winners have met rigorous criteria, including: unmet medical need, market potential, diversity of indications, strong science, multi-level partnering opportunities (biotech and pharma), potential for new opportunities beyond initial indications and corporate stability. As the industry leader in strategic analysis and transaction tracking, our main goal is to give these companies exposure to potential investors, partners, and acquirers." More details can be found at http://www.elsevierbi.com/mkt/Conf/TAP2013/PresentingCos.

Dr. Tony Yu, Vice President of Clinical Trial Operations, will be presenting on behalf of the company. His presentation is at 10:30 AM EST, Tuesday, Nov. 19.

About Elsevier Business Intelligence

Elsevier Business Intelligence, a global leader in the field of healthcare industry information, provides business intelligence on regulatory, business and reimbursement issues that are vital to the healthcare industry. Through a range of products including publications, conferences, e-learning, databases and reports, Elsevier Business Intelligence places biopharma and medical device professionals, and those who focus on these industries, at the forefront of knowledge, by providing the perfect combination of news and information together with penetrating insight and analysis. Our leading publications include PharmAsia News, IN VIVO and "The Pink Sheet." For more information, visit: http://www.ElsevierBi.com.

About Genelux Corporation

Headquartered in San Diego, California, Genelux Corporation is a privately held, clinical stage biopharmaceutical company dedicated to fundamentally changing the way in which cancer is diagnosed and treated. The company has developed a proprietary oncolytic vaccinia virus-based technology platform that can be engineered to insert specific diagnostic and/or therapeutic genes for delivery and amplification in cancer cells without harming healthy cells. This platform includes a green fluorescent protein (GFP) as a bioluminescent diagnostic. The company is also incorporating advanced diagnostic deep-tissue imaging technologies into its viral platform to enable highly specific visualization of tumors and circulating cancer cells. GL-ONC1, the company's lead product candidate, is an attenuated vaccinia virus (Lister strain) that is currently under evaluation in multiple human clinical trials in the US and Europe. For more information please visit http://www.genelux.com

Genelux Forward Looking Statement

Statements made about Genelux Corporation, other than statements of historical fact, reflect Management's current beliefs and assumptions founded on the data and information currently available to us. Statements of the company's progress, results, timing of pre-clinical and clinical trials and projections for product pipelines are examples of forward-looking statements. By definition, such undertakings involve risks, uncertainties and assumptions, and are subject to a number of such factors that could cause actual results to differ substantially from statements made, including but not limited to: risks associated with the success of clinical trials, research and development programs, regulatory approval processes for clinical trials, competitive technologies and products, patents, inception and/or continuation of corporate and other strategic partnerships and the need for additional funding or financing. 

Contacts:

Amy Berry
RCI Partners
415-793-2258
Email

Richard Roose
RCI Partners
415-202-4445
Email

Read more news from Genelux.

 


'/>"/>
SOURCE Genelux Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. BioSpace Spotlights Washington State Biotech Leaders
2. 2013 Top MLM Leader Awards Presented by ASEA, LLC
3. Regado Biosciences, Inc. Appoints World-Renowned Leader in Cardiovascular Research and Former Global Head of Cardiovascular Diseases for Merck & Co., to Board of Directors
4. ONL Announces Leadership Changes
5. ViaCyte Granted Over 20 Patents in 2013 Further Establishing the Company as a Leader in the Field of Regenerative Medicine
6. Bayer CropScience Supports 10th Anniversary of United Way Of The Greater Triangle’s Girls’ Leadership Development Initiative
7. MELA Sciences, Inc., a Leader in the Fight Against Melanoma, Participates in the American Society of Dermatologic Surgery Annual Meeting
8. IDC MarketScape Named Cloud-based Veeva a Leader in Life Sciences CRM
9. WIRB-Copernicus Group Leaders Speak at Global Clinical Research Summit in South Korea
10. BioSpace Spotlights Southern California Biotech Leaders
11. Sacom SPA, Leader in the Italian Green Biotechnology Fertilizer Industry, Enters the VedoGreen Financial Network
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... ... February 11, 2016 , ... Reichert Technologies, which ... today to pursue the highest level of accuracy and quality with the addition ... and the AR5 Refractometer. Accurate, reliable and tough enough for the most ...
(Date:2/10/2016)... BioAmber Inc. (NYSE: BIOA ), a leader in ... Co. Ltd., its partner in the Sarnia ... additional CDN$25 million in the joint venture for 10% ... 40%.  Mitsui will also play a stronger role in ... Sarnia , providing dedicated resources alongside BioAmber,s commercial ...
(Date:2/10/2016)... , Feb. 10, 2016 NX Prenatal Inc., ... proprietary NeXosome® technology for early warning of adverse ... most recent study by Dr. Thomas McElrath ... Society for Maternal Fetal Medicine,s (SMFM) annual meeting held ... th , 2016.  The presentation reported initial positive ...
(Date:2/10/2016)... (NYSE MKT: ISR), a medical technology company and innovator ... treatment of prostate, brain, lung, head and neck and ... second quarter and six months of fiscal 2016, which ... --> Revenue was $1.19 million for ... 31, 2015, a 12% increase compared to $1.07 million ...
Breaking Biology Technology:
(Date:2/2/2016)... MOUNTAIN VIEW, Calif. , Feb. 2, 2016 ... diabetic retinopathy market, Frost & Sullivan recognizes US-based ... North America Frost & Sullivan Award for New ... technology provider in North America ... standard in the rapidly growing diabetic retinopathy market. ...
(Date:1/28/2016)... SYNA ), a leading developer of human interface solutions, today ... --> --> Net revenue ... to the comparable quarter last year to $470.5 million. Net income ... $0.93 per diluted share. --> ... 2016 grew 9 percent over the prior year period to $60.3 ...
(Date:1/22/2016)... , January 22, 2016 /PRNewswire/ ... announced the addition of the  "Global ... their offering. --> http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ... the  "Global Behavioral Biometric Market 2016-2020" ... Research and Markets ( http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) ...
Breaking Biology News(10 mins):